ASH 2019 | Onvansertib with cytarabine or decitabine for R/R AML

Amer Zeidan

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the ongoing phase 1b dose-escalation trial (NCT03303339) evaluating the safety, efficacy and correlative analyses of onvansertib, a PLK-1 inhibitor, in combination with either low-dose cytarabine or decitabine in relapsed/refractory acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter